The anti-infective drug market is seeing strong growth due to multiple interrelated factors. One key driver is the rising incidence of specific infectious diseases, including healthcare-associated ...

The FDA is reviewing the resubmitted NDA for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections (UTIs) in adult women. Sulopenem etzadroxil is an ...

The Urinary Tract Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis ...

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract ... the development of new anti-infectives and gives the drug patent protection in ...

Pritelivir mesylate is under clinical development by AiCuris Anti-infective Cures and currently in Phase II for Genital Herpes. According to GlobalData, Phase II drugs for Genital Herpes have a 30% ...

US and MCUG for all children aged <2 years. 99m Tc–DMSA scan in high-grade reflux [3] Urinary tract infection (UTI) is the most common serious bacterial infection in childhood, and its ...

FDA Decision Expected by PDUFA Goal Date of October 25, 2024Potential to be First Oral Penem Approved in the U.S.DUBLIN and CHICAGO, Sept. 10, ...

The products in Uqora’s Complete Regimen are designed to work with each other to support consumers’ urinary health in multiple ways through safe, effective, high-quality ingredients ...

Antimicrobials, which include antibiotics, antivirals, antifungals, and antiparasitic drugs, are essential for preventing and ... The study was conducted at RCE’s Anti-Infective Research (AIR) unit ...